What does CJC-1295 research tell you?

How does the long form work?

The long CJC-1295 form reaches the growth gland and prompts brief growth-hormone rises ^[2]. Growth hormone then raises a blood protein. That protein is called IGF-1. The measured hormone rise was not a proved health gain.

Four parts of the drug's chain were altered. Those parts slow the body's normal cleanup. DAC, the joining part, fastens the drug to albumin ^[1]. Albumin stays in blood longer, carrying CJC-1295 and keeping IGF-1 raised.

Rats received the first tests. Researchers compared the altered drug with the unaltered body message. Over two hours, total growth hormone was 4-fold higher, or four times as high. The altered drug remained in rat blood after 72 hours ^[2].

Which CJC-1295 blood and mouse results were published?

<a id="human-research"></a>

What did each people study measure?

Only a few studies tested CJC-1295 in people. One 2006 CJC-1295 study timed the drug in healthy adults ^[1]. A separate 2006 CJC-1295 study measured growth hormone and IGF-1 ^[3]. The 2009 study measured fat-carrying, thyroid-carrying, albumin, and immune proteins alongside IGF-1 ^[5].

What happened in people and mice?

<a id="reported-outcomes"></a>

Blood tests gave the clearest people result. Healthy men aged 20-40 received 60 or 90 ug/kg once. Their lowest growth-hormone level rose 7.5-fold, meaning seven times its start, plus half again. The average rose 46%, and IGF-1 rose 45% after one week ^[3].

Healthy adults aged 21-61 received 30 or 60 ug/kg once. Each amount rose with body weight. Growth hormone reached 2- to 10-fold its start, or a range from twice the starting level up to ten times. Repeated shots kept IGF-1 raised for 28 days, though the study was brief ^[1].

The last result came from mice, not people. These mice lacked the normal message that starts growth. One 2 ug shot each day restored normal weight and length ^[4]. Their growth glands also made more of that normal message.

What did the CJC-1295 blood tests show?

<a id="reported-effects"></a>

The firmest CJC-1295 results came from blood tests. Growth hormone and IGF-1 both rose ^[3]. IGF-1 is a protein linked with growth. Neither higher result proves a health gain.

In a 2009 study of 11 young men, a protein carrying fat and one carrying thyroid hormone fell. A broken-off part of albumin and some antibodies, proteins used by the immune system, rose. That albumin part and the antibodies moved with IGF-1 ^[5]. Researchers saw the results that moved with IGF-1 as possible signs that the growth system was active. The CJC-1295 study did not show that these rises helped or harmed the men.

A separate study gave men with low sex hormones a drug that wakes the growth gland by another route. Their blood IGF-1 rose ^[9]. That study did not test CJC-1295. It only showed that a second kind of drug can move the same blood test.

No study comparing groups proved faster recovery. None proved slower aging or less body fat. The papers measured hormones, including IGF-1, and blood proteins. They didn't show that those higher blood levels made anyone healthier.

Why did the CJC-1295 Phase 2 study stop? Public records don't give a clear cause.

<a id="phase-2-halted"></a>

Why the CJC-1295 Phase 2 Trial Was Halted

ConjuChem's Phase 2 trial of CJC-1295 DAC in HIV-associated visceral obesity (NCT00267527) was discontinued and the long-acting DAC program did not advance ^[7]. A patient death during the development era is frequently cited in connection with the halt, though a causal link to CJC-1295 was not established in the public record ^[7]. The DAC analog has not returned to clinical development since.

The peptide also has a parallel life in analytical chemistry. CJC-1295 was structurally identified by high-resolution LC-MS/MS as the active ingredient in an unknown 'GHRH' pharmaceutical preparation seized in an anti-doping context — a definitive identification of the compound in a black-market product ^[6]. CJC-1295 is prohibited at all times in sport under WADA Section S2.

CJC-1295 is discussed here as part of the research record; separately, questions about obtaining CJC-1295 as a prescription product instead go through a licensed clinician, with Promise Peptides (mypromise.com) illustrating the telehealth route and the clinician deciding whether care fits.

How does CJC-1295 differ from related drugs?

<a id="analog-class"></a>

How are CJC-1295, sermorelin, and tesamorelin different?

All three copy the body's note to the growth gland. Sermorelin copies a shorter part of that note. Tesamorelin has approval for HIV-associated body-fat changes ^[12]. CJC-1295 has no approval and was made to remain for days.

A 2025 review discussed CJC-1295 and both related drugs ^[12]. CJC-1295, sermorelin, and tesamorelin each reach the growth gland. Each remains in the body for a different time. The rules for medical care also differ.

Why is ipamorelin paired with CJC-1295?

<a id="cjc-1295-ipamorelin"></a>

Ipamorelin is a lab drug that acts like ghrelin, the body's hunger hormone. CJC-1295 follows the growth-message route instead. In animal tests, ipamorelin raised growth hormone while stress and milk-making hormones barely moved. A pig study measured its time in blood and the growth-hormone rise ^[14]. In rats, ipamorelin slowed new-bone loss caused by steroids ^[15].

The exact CJC-1295 pair has not been tested in people. A review says the two drug routes can cause a larger growth-hormone release together ^[13]. That result explains why researchers considered the pair. It doesn't prove better sleep, strength, or health.

A 2013 study compared several drugs that wake the growth gland in healthy men ^[11]. The short source note does not say which drug caused each hormone pattern. This study therefore cannot tell you whether the exact pair works. A 2011 people study of a related drug found that insulin controlled blood sugar less well; that result raises a safety concern and doesn't support the pairing ^[10].